{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T07:00:25Z","timestamp":1776322825682,"version":"3.50.1"},"reference-count":18,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2014,10,14]],"date-time":"2014-10-14T00:00:00Z","timestamp":1413244800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Contact Dermatitis"],"published-print":{"date-parts":[[2014,12]]},"abstract":"Summary<\/jats:title>Background<\/jats:title>Omeprazole is a proton pump inhibitor for the treatment of gastric acid\u2010related disorders. In recent years, reports of dermatitis upon exposure to omeprazole during manufacture have been noted.<\/jats:p><\/jats:sec>Objective<\/jats:title>To present diagnostic findings in workers who reported suspected hypersensitivity reactions resulting from occupational exposure to omeprazole.<\/jats:p><\/jats:sec>Methods<\/jats:title>Ninety\u2010six workers exposed to omeprazole during the manufacturing process underwent investigation by the AstraZeneca O<\/jats:styled-content>ccupational H<\/jats:styled-content>ealth C<\/jats:styled-content>entre (S<\/jats:styled-content>\u00f6dert\u00e4lje, S<\/jats:styled-content>weden) for suspected allergy. All subjects underwent a lymphocyte transformation test (LTT<\/jats:styled-content>) and a skin test within 6 months of the clinical reaction. Predictive tests on guinea\u2010pigs were conducted to establish omeprazole's sensitizing potential.<\/jats:p><\/jats:sec>Results<\/jats:title>Thirty\u2010one subjects with clinical symptoms had a positive LTT<\/jats:styled-content> result. Twenty\u2010eight subjects had positive patch test results; of these, 23 also had a positive LTT<\/jats:styled-content> result (sensitivity of the LTT<\/jats:styled-content>: 82%). Fifty\u2010six subjects had negative patch test results; 46 of these had a negative LTT<\/jats:styled-content> result (specificity: 82%). All subjects who underwent prick testing (n = 18) had negative results. Delayed contact hypersensitivity was observed in 18 of 20 test animals.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>These findings confirm the risk of sensitization to omeprazole from occupational exposure. They are of importance for the development of new formulations of omeprazole, or its enantiomers, in light of the potential for inducing skin allergy.<\/jats:p><\/jats:sec>","DOI":"10.1111\/cod.12305","type":"journal-article","created":{"date-parts":[[2014,10,14]],"date-time":"2014-10-14T05:37:40Z","timestamp":1413265060000},"page":"371-375","source":"Crossref","is-referenced-by-count":20,"title":["Sensitization to omeprazole in the occupational setting"],"prefix":"10.1111","volume":"71","author":[{"given":"Per Hamid","family":"Ghatan","sequence":"first","affiliation":[{"name":"AstraZeneca, OSHE Department SE\u2010151 85 S\u00f6dert\u00e4lje Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maritha","family":"Marcusson\u2010St\u00e5hl","sequence":"additional","affiliation":[{"name":"Department of Molecular Toxicology\/Immunotoxicology, Safety Assessment, AstraZeneca R&D SE\u2010151 85 S\u00f6dert\u00e4lje Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihaly","family":"Matura","sequence":"additional","affiliation":[{"name":"Centre for Occupational and Environmental Medicine, Stockholm County Council, Solnav\u00e4gen 4 SE\u2010113 65 Stockholm and Institute of Environmental Medicine, Karolinska Institutet SE\u2010171 76 Stockholm Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol","family":"Bj\u00f6rkheden","sequence":"additional","affiliation":[{"name":"Department of General Toxicology Sciences, Safety Assessment, AstraZeneca R&D SE\u2010151 85 S\u00f6dert\u00e4lje Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per","family":"Lundborg","sequence":"additional","affiliation":[{"name":"AstraZeneca R&D SE\u2010431 83 M\u00f6lndal Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Cederbrant","sequence":"additional","affiliation":[{"name":"Department of Molecular Toxicology\/Immunotoxicology, Safety Assessment, AstraZeneca R&D SE\u2010151 85 S\u00f6dert\u00e4lje Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,10,14]]},"reference":[{"key":"e_1_2_7_2_1","unstructured":"AstraZeneca.2012. Available at:http:\/\/www.medicines.org.uk\/EMC\/searchresults.aspx?term=losec+capsules&searchtype=QuickSearch(last accessed 31 July 2014)."},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.2007.00921.x"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.2011.01931.x"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1053\/AC.2000.6343"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.1986.tb01259.x"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/0887-2333(94)90233-X"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.1975.tb05311.x"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.1969.42"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1586\/1744666X.2.6.887"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1159\/000104215"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/00220345990780081101"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1159\/000237456"},{"key":"e_1_2_7_14_1","unstructured":"AstraZeneca.Omeprazole safety data sheet 2012."},{"key":"e_1_2_7_15_1","unstructured":"AstraZeneca.Esomeprazole safety data sheet 2012."},{"key":"e_1_2_7_16_1","first-page":"228","article-title":"Nine cases of allergy to omeprazole","volume":"22","author":"Abdul Razzak E","year":"2012","journal-title":"J Investig Allergol Clin Immunol"},{"key":"e_1_2_7_17_1","first-page":"57","article-title":"Nine cases of omeprazole allergy: cross\u2010reactivity between proton pump inhibitors","volume":"19","author":"Lobera T","year":"2009","journal-title":"J Investig Allergol Clin Immunol"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/cod.12306"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/cod.12283"}],"container-title":["Contact Dermatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcod.12305","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cod.12305","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T16:47:09Z","timestamp":1696351629000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cod.12305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,14]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["10.1111\/cod.12305"],"URL":"https:\/\/doi.org\/10.1111\/cod.12305","archive":["Portico"],"relation":{},"ISSN":["0105-1873","1600-0536"],"issn-type":[{"value":"0105-1873","type":"print"},{"value":"1600-0536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,14]]}}}